Bcl-2 blocks 2-methoxyestradiol induced leukemia cell apoptosis by a p27\textsuperscript{Kip1}-dependent G1/S cell cycle arrest in conjunction with NF-\textkappaB activation

Christina Batsi\textsuperscript{a}, Soultana Markopoulou\textsuperscript{a}, Evangelos Kontargiris\textsuperscript{a}, Christiana Charalambous\textsuperscript{b}, Christoforos Thomas\textsuperscript{a}, Savvas Christoforidis\textsuperscript{c,d}, Panagiotis Kanavaro\textsuperscript{e}, Andreas I. Constantinou\textsuperscript{b}, Kenneth B. Marcu\textsuperscript{f,g,*}, Evangelos Kolettas\textsuperscript{a,d,*}

\textsuperscript{a}Cell and Molecular Physiology Unit, Laboratory of Physiology, School of Medicine, University of Ioannina, 45110 Ioannina, Greece  
\textsuperscript{b}Department of Biological Sciences, University of Cyprus, 1678 Nicosia, Cyprus  
\textsuperscript{c}Laboratory of Biological Chemistry, School of Medicine, University of Ioannina, 45110 Ioannina, Greece  
\textsuperscript{d}Biomedical Research Institute, Foundation for Research and Technology, University Campus, 45110 Ioannina, Greece  
\textsuperscript{e}Laboratory of Anatomy, Histology and Embryology, School of Medicine, University of Ioannina, 45110 Ioannina, Greece  
\textsuperscript{f}Department of Biochemistry and Cell Biology, Institute for Cell and Developmental Biology, Stony Brook University, New York 11794-5215, NY USA  
\textsuperscript{g}Centro Ricerca Biomedica Applicata (CRBA), LAB. Centralizzato, St. Orsola University Hospital, University of Bologna, 40138, Bologna, Italy

1. Introduction

2-Methoxyestradiol (2-ME2), a catechol estrogen, is a natural metabolic by-product of 17\beta-estradiol that acts independently of estrogen receptors to inhibit angiogenesis and tumor cell proliferation and to induce apoptosis in vitro and in vivo [1–8].

Multiple discrete mechanisms are involved in the specific anti-proliferative action of 2-ME2 in tumor cells including both G1/S and G2/M cell cycle phase arrest. 2-ME2 was shown to arrest the growth of many human cancer cell lines in vitro, including, Jurkat cells [9], multiple myeloma [10], epithelial [11–16], melanoma [17] and medulloblastoma cancer cells [18] and transformed fibroblasts [19] in G2/M phase. G2/M cell cycle arrest was characterized by the induction of cyclin B and Cdc2 kinase activity [9,11,13,17]. Others, however, showed that 2-ME2 inhibited the growth of pancreatic cancer cells by prolonging S-phase [20] or by inducing both G1/S and G2/M arrest of human osteosarcoma cells [21] or of pancreatic cell lines [22]. In contrast, 2-ME2 had no effect on the growth of normal cells [13,15,17,19,23] including lymphocytes [24]. The induction of apoptosis by 2-ME2 in tumor cells...
involves different molecular mechanisms. While several studies suggested that 2-ME2 can induce apoptosis both by p53-dependent and p53-independent mechanisms in various tumor cell types [8,13,15,17–19,23,25,26], scant evidence exists implicating NF-κB in 2-ME2-induced apoptosis [18,27]. While p38/JNK-dependent NF-κB activation was required for 2-ME2-induced apoptosis in prostate cancer cells [27], in contrast a reduction in NF-κB transcriptional and DNA binding activity was observed in 2-ME2-induced apoptosis of medulloblastoma cells [18].

Further studies have implicated the anti-apoptotic members of the Bcl-2 family in 2-ME2-induced apoptosis [15,27–30]. The Bcl-2 family comprises two mutually opposing groups of proteins including: anti-apoptotic Bcl-2 and Bcl-XL and pro-apoptotic Bak and Bax. While several models have been proposed to explain the mechanism by which Bcl-2 family members regulate apoptosis, the ratio of anti-apoptotic:pro-apoptotic Bcl-2 family members is one key factor dictating the relative sensitivity or resistance of cells to a wide variety of apoptotic stimuli [31–33]. In addition, Bcl-2 and Bcl-XL are regulated by phosphorylation in their flexible loop between the BH4 and BH3 domains, which determines their cytoprotective function in response to cellular stresses as well as growth and survival factors [34]. Bcl-2 phosphorylation by ERK1/2 and PKCα kinases, either at the unique Ser70 residue or at multiple Thr69, Ser70, and Ser89 sites, positively regulates Bcl-2 anti-apoptotic function [35]. However, c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK)-mediated phosphorylation of Bcl-2 at multiple-sites hinders Bcl-2 survival function in paclitaxel-induced apoptosis [36,37]. Thus, the type of stimulus, the regulatory pathways involved, and the degree and duration of phosphorylation at specific Bcl-2 residues produce different outcomes.

In response to 2-ME2, both Bcl-2 [15,27–29] and Bcl-XL [22,30] are inactivated by phosphorylation at Ser70 and Ser62, respectively, mediated by JNK but not ERK1/2 [27,29,30,37]. Whether Bcl-2 phosphorylation induced by microtubule destabilizing agents such as taxol [37–39] or 2-ME2 [15,27–29] interferes with the heterodimerization of Bcl-2 to Bax remains elusive [37–39]. However, JNK-mediated phosphorylation of Bcl-2 leading to its inactivation in response to 2-ME2 will allow the pro-apoptotic members of the Bcl-2 family, to drive the cell towards death [31–33].

2-ME2-induced phosphorylation of Bcl-2, mediated by JNK/SAPK, has been correlated with apoptosis of prostate [15,27] and leukemia cells [29]. Activation of JNK by 2-ME2 appears to be due to its ability to potently inhibit superoxide dismutase [40] resulting in enhanced formation of ROS [7,24–26,40] and Akt inhibition [26] to selectively kill tumor cells [24–26,40].

Although available data point to Bcl-2 phosphorylation as a key executing signal for 2-ME2-induced apoptosis, Bcl-2’s mechanisms of action in this context and its ability to protect cells from 2-ME2-induced apoptosis both remain undefined. We show here that 2-ME2 treatment of leukemia cells promoted a p53-independent apoptotic response characterized by Bcl-2 down-regulation and phosphorylation mediated by JNK/SAPK, Bak up-regulation, proteolytic cleavages of caspases-9,-3 and PARP-1. Moreover, ectopic over-expression of Bcl-2 in leukemia cells prevented all of these aspects of the 2-ME2-induced apoptotic response by orchestrating a p27Kip1-dependent G1/S phase arrest in conjunction with activating NF-κB.

2. Materials and methods

2.1. Cell culture

Human Jurkat T lymphoma cells (clone E6-1) were cultured in RPMI-1640 and amphotropic Phoenix cells in DMEM supplemented with 10% FCS (all from Biochrom AG, Germany), 2 mM L-glutamine, 100 units/ml penicillin and 100 μg/ml streptomycin (PAA Laboratories, Germany) at 37 °C, 5% CO2.

2.2. Retroviral vectors and generation of infected Jurkat cells

The retroviral vectors pBabe-Puro and pBabe-Puro/Bcl-2 carrying human Bcl-2 cDNA [41] pSR-Puro (referred to as Vector thereafter) and pSR-Puro carrying p27Kip1 shRNA (referred to as p27P, thereafter) [42] have been described elsewhere. IBIN was a retroviral vector carrying a trans-dominant IkBα (S32A/S36A) super repressor (IkBαSR), with serines 32 and 36 mutated to alanines, in addition to Neo as a selection marker was described previously [43].

Jurkat cells were infected overnight in suspension with high titers of retroviruses generated using amphotropic Phoenix cells. The infected Jurkat cells were centrifuged, the virus-containing supernatant was aspirated and the cell pellets were washed once in serum-free RPMI-1640 and incubated in complete RPMI-1640 growth medium for 48 h before being subjected to selection with 1 μg/ml puromycin (Sigma Co., Germany) for two weeks or to 0.5–1.0 mg/ml G418 (Geneticin) (Gibco/Invitrogen, UK) for three weeks.

2.3. Treatment of Jurkat cells with 2-methoxyestradiol

All Jurkat cells plated at 1.5 × 10⁶ cells per 10 cm dish were treated with 0.5–10 μM 2-ME2 (Sigma Co., Germany), dissolved in ethanol or with ethanol vehicle as control for different periods of time. Treated and untreated cells were harvested and DNA and proteins were extracted and analyzed as described below.

2.4. Growth of uninfected and retrovirus-infected Jurkat cells

Cells were plated at a density of 1.0 × 10⁵ cells per well in 24-mutiwell plates in complete growth medium in the presence or absence of 1.0 μM 2-ME2 or ethanol. Cell growth was monitored over a period of 9 days. The experiment was repeated three times and growth curves were constructed.

2.5. Flow cytometric analysis

1.5 × 10⁶ exponentially growing Jurkat cells were incubated in complete growth medium in the presence or absence of 0.5 μM and 1.0 μM 2-ME2 or ethanol for 12 h and 24 h. The cells were collected by centrifugation, and processed for flow cytometric analysis on a Becton Dickinson FACScan flow cytometer as described previously using a CycleTEST PLUS DNA kit (Becton Dickinson, CA, USA), according to manufacturer’s instructions.

2.6. DNA fragmentation assay

1.5 × 10⁶ Jurkat cells grown in complete growth medium were treated with increasing concentrations of 2-ME2 or ethanol for different periods of time. Low molecular weight DNA was extracted and analyzed as described previously [44].

2.7. Quantification of apoptosis using annexin V/PI

Simultaneous flow cytometric quantification of apoptotic and viable cells was performed with an annexin V/propidium iodide kit (Annexin V-FITC/PI) (Assay Designs, Ann Arbor, Michigan, USA). Untreated and 2-ME2-treated Jurkat cells were collected by centrifugation, resuspended in 1 × binding buffer, incubated with annexin-FITC and propidium iodide and analyzed by flow
cytometry (CyFlow ML, Partec, Germany) according to the manufacturer’s instructions.

2.8. Preparation of cytoplasmic and nuclear extracts and isolation of nuclei

Cytoplasmic and nuclear extracts were prepared essentially as described previously [45]. Nuclei were isolated through sucrose gradients essentially as described previously [46]. Protein concentration was determined using a BioRad protein assay reagent. The extracts were stored at –80°C or used immediately for Western blotting.

2.9. Isolation of total proteins and Western blot analysis

1.5 × 10⁶ Jurkat cells grown in complete growth medium were treated with 0.5 μM and 1.0 μM 2-ME2 or ethanol for 24 h. The cells were collected by centrifugation and total proteins were extracted and analyzed by western immunoblotting, as described previously [44]. Antibodies used were: Mouse monoclonals to Bcl-2 (sc-509), cyclin D3 (sc-6283), E2F1 (sc-251), pRb (sc-102), p16INK4a (sc-1661) (Santa Cruz Biotech, Germany), p21cip1/Waf1 (Ab-1, OP64), p27kip1 (NCL-p27; Novacatsra Ltd. or M-7203; DakoCytomation, Denmark), caspase-8 (sc-5263), PARP-1 (Cl-10; BD Transduction Laboratories), caspase-3 (sc-7272) and β-actin (A5441; Sigma Co, Germany), rabbit polyclonals to JNK/SAPK (9252) and phospho-JNK/SAPK (Thr182/Tyr185) (#9251) (Cell Signaling, USA), Bak (A3538; Dako), cyclin E (sc-481), caspase-9 (sc-8355), NF-κB p65 (sc-372) and lamin B and goat polyclonals to NF-κB p50 (sc-1190) and Pim-2 (ab13616; Abcam Ltd., UK), followed by horseradish peroxidase (HRP)-conjugated secondary antibodies. Antibody binding was detected using an ECL detection kit (GE HealthCare, Bucks, UK).

3. Results

3.1. Induction of Jurkat cell apoptosis by 2-ME2

Actively proliferating Jurkat cells were treated with different concentrations of 2-ME2 ranging from 0.5 μM to 10 μM or ethanol as a negative control for 24 h and 48 h and low molecular weight DNA was extracted and analyzed by agarose gel electrophoresis (Fig. 1A). Whereas ethanol-treated cells did not undergo apoptosis, 2-ME2-treated Jurkat cells exhibited DNA fragmentation, producing a DNA ladder characteristic of cells undergoing apoptosis even with 2-ME2 as low as 0.5–1.0 μM. Based on the densities of DNA fragmentation patterns, the extent of apoptosis appeared to be higher in cells treated with 2-ME2 for 48 h vs. 24 h (Fig. 1A). Moreover, Jurkat cells were treated with 0.5 μM and 1.0 μM 2-ME2 or ethanol for 0–24 h exhibited a marked induction of apoptosis at 8 h, which became more pronounced at 12 h and 24 h at both concentrations (Fig. 1B).

Apoptosis of Jurkat cells treated with 2-ME2 was further evaluated by flow cytometry (Fig. 1C). Jurkat cells treated with 2-ME2 for 12 h or 24 h exhibited a decrease in the G1 population due to the appearance of a considerable fraction of 2-ME2-treated cells as a sub-G1 population indicative of 2-ME2-induced apoptosis. The sub-G1 cell population undergoing apoptosis increased from 2.2% in the ethanol-treated cells to 24% and 26.3% following treatment of the cells with 0.5 μM and 1.0 μM 2-ME2 for 12 h, respectively (Fig. 1C). 2-ME2 treatment at 0.5 μM and 1.0 μM respectively for 24 h produced much higher proportions of 39.6% and 42.2% of sub-G1 apoptotic cells vs. only 5% for ethanol treated controls. Collectively, these data show that 2-ME2 induced apoptosis of Jurkat cells in a time- and dose-dependent manner.

![Fig. 1. Induction of apoptosis of Jurkat cells by 2-ME2. (A) Dose-dependent induction of apoptosis of Jurkat cells. 1.5 × 10⁶ cells were treated with increasing concentrations of 2-ME2 for 24 h and 48 h as indicated or ethanol (Et) as control and low molecular weight DNA was extracted and analyzed by agarose gel electrophoresis. (B) Time-dependent apoptosis of Jurkat cells. 1.5 × 10⁶ cells were treated with 0.5 μM and 1.0 μM of 2-ME2 or Et for different periods of time as indicated and low molecular weight DNA was extracted and analyzed by agarose gel electrophoresis. (C) Analysis of apoptosis of asynchronous cultures of Jurkat cells treated with 2-ME2 as determined by flow cytometry. Cells treated with 0.5 μM and 1.0 μM of 2-ME2 or Et for 12 h and 24 h were subjected to flow cytometric analysis as described under Section 2. Results were reproduced in two independent experiments.](image-url)
3.2. Enforced Bcl-2 expression suppressed 2-ME2-induced apoptosis

Next we directly investigated the effects of Bcl-2 in this response by comparing the properties of Jurkat cells stably transduced with a human Bcl-2 retroviral vector vs. a puromycin (Puro) empty vector control. Western blot analysis showed that the Bcl-2-transduced cells expressed the 26 kDa human Bcl-2 protein at much higher levels than parental Jurkat or Jurkat Puro control cells (Fig. 2A). Jurkat Puro and Jurkat Bcl-2 cell populations were treated with 2-ME2 or ethanol for 24 h and their genomic DNA was subjected to agarose gel electrophoresis (Fig. 2B). Whereas 2-ME2 induced apoptosis in a dose-dependent manner in the control cells, enforced Bcl-2 expression blocked this apoptotic response.

One of the likely mechanisms of 2-ME2-induced apoptosis involves the phosphorylation and inactivation of the anti-apoptotic Bcl-2 protein [15,27–29]. As shown in Fig. 2C, 2-ME2 down-regulated and triggered the phosphorylation of Bcl-2 in Jurkat and Jurkat Puro cells, compared to their untreated or ethanol-treated controls, thus confirming these previous reports [15,27–29]. Although phosphorylated Bcl-2 protein was also present in 2-ME2-treated Jurkat Bcl-2 cells, its level of expression remained high following 2-ME2 exposure (Fig. 2C). Thus, because most of the overexpressed Bcl-2 was not phosphorylated, this could in part explain why the additional Bcl-2 was protective against apoptosis. Because Bcl-2 phosphorylation inactivates the protein and may interfere with its dimerization with pro-apoptotic partner proteins [36–38], we next investigated the expression of the pro-apoptotic Bcl-2 family member, Bak, which was previously shown to play a key role in Jurkat cell apoptosis [47,48]. Western blot analysis showed that while Bak expression was modestly induced in Jurkat and Jurkat Puro cells, it remained unaffected in Jurkat Bcl-2 cells (Fig. 2C). Thus the Bcl-2:Bak ratio was shifted towards the former in Jurkat Bcl-2 cells.

Because JNK/SAPK-mediated phosphorylation of Bcl-2 inactivates its anti-apoptotic function [27,29,30,36,37], we also investigated the expression of total and phospho-JNK/SAPK by immunoblotting (Fig. 2D). Indeed, 2-ME2 induced JNK activation, as revealed by enhanced amounts of phosphorylated p46 and p54 forms of JNK/SAPK in Jurkat and Jurkat Puro cells and phospho-p54 in Jurkat Bcl-2 cells. In response to 2-ME2, these latter activated JNKs correlated well with Bcl-2 phosphorylation (Fig. 2C), but only p54 phosphorylation was enhanced in 2-ME2 treated Jurkat Bcl-2 cells (Fig. 2D).

Next to further elaborate the mode of action of Bcl-2 in this context, we examined the status of caspases-9, -8 and -3 and PARP-1. Western blot analysis detected two bands of ∼50 kDa and 35 kDa corresponding to caspase-9 (Fig. 2E). While treatment of Jurkat and Jurkat Puro cells with 2-ME2 resulted in a reduction in the levels of p35 compared to their untreated or ethanol-treated cells, no change in the levels of p35 were detected in 2-ME2-treated Jurkat Bcl-2 cells (Fig. 2E). In contrast, no change in the expression levels of caspase-8 was detected using two different antibodies (data not shown). Immunoblotting also revealed that procaspase-3 was in its 32 kDa unprocessed form in untreated Jurkat and Jurkat Puro cells, but 2-ME2-treated cells presented procaspase-3 as 20 kDa and 17 kDa cleaved forms in addition to the inactive 32 kDa proform (Fig. 2E). In contrast, caspase-3 in 2-ME2-treated Bcl-2-expressing Jurkat cells remained in its inactive 32 kDa proform (Fig. 2E). Cleavage of poly-(ADP ribose)-polymerase (PARP-1), a caspase-3 substrate, is also a hallmark of cells undergoing apoptosis by a variety of apoptotic stimuli. Immunoblot analysis showed that whereas untreated and ethanol-treated Jurkat and Jurkat Puro cells expressed the intact 115 kDa enzyme, cells treated with 2-ME2 contained the intact 115 kDa band and an 89 kDa cleavage product (Fig. 2E). In contrast, in untreated, ethanol-treated or 2-ME2-treated Jurkat-Bcl-2 cells only the intact 115 kDa form of PARP-1 was detected (Fig. 2E). Taken together these data showed that 2-ME2-induced apoptosis by the mitochondrial pathway was effectively blocked by ectopic expression of Bcl-2 in Jurkat cells.
3.3. Bcl-2-mediated apoptotic block correlated with G1/S cell cycle arrest following 2-ME2 treatment

To investigate whether overexpression of Bcl-2 affected the proliferation of Jurkat cells in the presence or absence of 2-ME2, growth curves were constructed (Fig. 3A). Overexpression of Bcl-2 in Jurkat cells altered their growth rate compared to their vector-infected (Jurkat Puro) or uninfected (Jurkat) counterparts. Jurkat Bcl-2 cells grew slower than either Jurkat or Jurkat Puro cells (Fig. 3A) with a doubling time of 27.5 h compared to 20.8 h and 20.9 h for their control counterparts, respectively. In contrast, cells treated with 2-ME2 presented a very different growth profile. While 2-ME2 treated Jurkat and Jurkat Puro cells decreased dramatically in cell numbers due to apoptosis, the cell numbers of Bcl-2-expressing Jurkat cells remained constant over a period of 9 days (Fig. 3A).

Next we performed annexin V/PI staining to simultaneously quantify apoptotic and live cells (Fig. 3B) by flow cytometric analysis (Fig. 3C). Annexin V/PI staining showed that Jurkat Puro cells exhibited a dose-dependent decrease in live cells and an increase in the percentage of apoptotic cells from 5.8% to 34.35% and 37.25% after treatment with ethanol, 0.5 μM and 1.0 μM 2-ME2 for 24 h, respectively (Fig. 3B). In contrast, Jurkat Bcl-2 were more resistant to 2-ME2 treatment maintaining a higher percentage of live cells and exhibiting an increase in the percentage of apoptotic cells from 5.4% to 14.56% and 15.24% after treatment with ethanol or 0.5 μM and 1.0 μM 2-ME2 for 24 h, respectively (Fig. 3B).

Flow cytometric analysis of control and 2-ME2 treated Jurkat Puro and Bcl-2 cells were in agreement with the above annexin V/PI results. For Jurkat Puro cells the sub-G1 peak specifying apoptotic cells increased from 5% in the ethanol control to 27.8% and 33.4%...
after 12 h in 0.5 \text{mM} and 1.0 \text{mM} 2\text{-ME2} respectively, and from 3.6% in to 38.5% and 40.4% in response to the same 2\text{-ME2} doses for 24 h (Fig. 3C). In sharp contrast, Bcl-2 over-expression protected Jurkat cells from 2\text{-ME2} induced apoptosis with their sub-G1 population increasing from 4% to only 5.7% and 13% after 12 h in to 0.5 \text{mM} and 1.0 \text{mM} 2\text{-ME2} and up to 14.8% and 16.1% in response to 24 h of 0.5 \text{mM} and 1.0 \text{mM} 2\text{-ME2} (Fig. 3C). Moreover, Bcl-2 also induced G1/S cell cycle phase arrest following treatment with 2\text{-ME2} for 24 h compared to their control Jurkat Puro cells (Fig. 3C), consistent with cell growth curves (Fig. 3A).

Next, we screened for effects on effectors of cell cycle progression and apoptosis (including cyclins D3 and E, E2F1, pRb, p16\text{INK4A}, p21\text{Cip1/Waf1} and p27\text{Kip1}) by immunoblotting (Fig. 4). Cyclin D3 levels were down-regulated by 2\text{-ME2} in Jurkat and Jurkat Puro cells, but were maintained in Bcl-2-expressing cells. In contrast, the levels of cyclin E and E2F1, but not pRb, were down-regulated in all cell types in response to 2\text{-ME2} (Fig. 4). 2\text{-ME2} treatment of Jurkat cells also had differential effects on cyclin-dependent kinase inhibitors. p16\text{INK4A} expression was markedly induced by 2\text{-ME2} in control cells, which was prevented by Bcl-2 over-expression. Both CKIs p21\text{Cip1/Waf1} and p27\text{Kip1} were detected in all cell types with p27\text{Kip1} expressed at higher levels. 2\text{-ME2} down-regulated and induced the phosphorylation of p21\text{Cip1/Waf1} in each Jurkat cell type. However, p27\text{Kip1} levels remained unaffected by 2\text{-ME2}, although Jurkat Bcl-2 cells expressed ~2–3 fold more p27\text{Kip1} compared to Jurkat or Jurkat Puro cells (Fig. 4).

3.4. Nuclear-associated Bcl-2 enhanced the nuclear levels of p27\text{Kip1}

Because p27\text{Kip1} was not altered by 2\text{-ME2} and enhanced Bcl-2 expression has been associated with increased levels of p27\text{Kip1} [53–55] (Fig. 4), we investigated the subcellular localization of Bcl-2 and p27\text{Kip1} by indirect immunofluorescence and confocal laser scanning microscopy (supplementary information and Fig. 1S). Ethanol-treated Jurkat Puro cells expressed low levels of predominantly nuclear Bcl-2. However, after 2\text{-ME2} treatment, Bcl-2 was detected in the nuclear compartment and outside the cell nucleus due to cell damage and nuclear disruption. In contrast, untreated Jurkat Bcl-2 cells expressed much higher levels of cytoplasmic and nuclear Bcl-2 protein (Fig. S1A). Following 2\text{-ME2} treatment, Bcl-2 protein was still cytoplasmic but higher levels became associated with the nuclear membrane and nuclear matrix of intact nuclei (Fig. S1A).

p27\text{Kip1} was predominantly localized in the cytoplasm, around and loosely associated with intact nuclei of control Jurkat Puro cells (Fig. S1B) and its cytoplasmic localization was disrupted by 2\text{-ME2} treatment due to their compromised cell and nuclear integrity (Fig. S1B). In ethanol-control Jurkat Bcl-2 cells p27\text{Kip1} was strongly up-regulated in the cytoplasm and was also more tightly associated with intact nuclei (Fig. S1B). After 2\text{-ME2} exposure Jurkat Bcl-2, p27\text{Kip1} was still present in the cytoplasm but now at markedly higher levels in Jurkat Bcl-2 intact nuclei (Fig. S1B).
Proteins from sucrose gradient purified cell fractions of untreated, ethanol- or 2-ME2-treated Jurkat Puro and Jurkat Bcl-2 cells were also subjected to Bcl-2 immunoblotting. Bcl-2 was predominantly nuclear in Jurkat Puro and Jurkat Bcl-2 cells (Fig. 5A). In response to 2-ME2, phosphorylated Bcl-2 form was detected in cytoplasmic and nuclear extracts of both cell types and cytoplasmic Bcl-2 levels were reduced in control Jurkat Puro cells in response to 2-ME2 (Fig. 5A), suggesting differential regulation of these two different intracellular pools of Bcl-2 in Jurkat cell apoptosis [50]. Jurkat Bcl-2 cells presented higher levels of cytoplasmic and especially nuclear Bcl-2 protein in comparison to Jurkat Puro cells (Fig. 5A), which was also observed in nuclear extracts of Jurkat Puro and Jurkat Bcl-2 cells (Fig. 5B). Moreover the expression of nuclear phosphorylated and unphosphorylated forms of Bcl-2 was much higher in Bcl-2 over-expressing cells.

p27Kip1 immunoblotting of proteins from specific cell fractions and isolated nuclei, confirmed that 2-ME2 did not affect p27Kip1 levels in either Jurkat Puro or Jurkat Bcl-2 and also that p27Kip1 expression was much higher in Jurkat Bcl-2 (Fig. 5A and B). p27Kip1 was predominantly cytoplasmic in Jurkat Puro cells but in contrast was more prevalent in the nuclear extract of Jurkat Bcl-2 cells (Fig. 5A). The latter was in keeping with subcellular localization results (Fig. S1B) and was also confirmed with isolated nuclei of Jurkat Puro and Jurkat Bcl-2 cells (Fig. 5B). In addition, p27Kip1 migrated as a doublet band (particularly in Jurkat Bcl-2 cells), which may represent different sites of phosphorylation associated with either protein degradation (Thr187) or stabilization (Ser10) [56] (Fig. 5A and B).

3.5. Involvement of NF-κB in the resistance of Jurkat Bcl-2 cells to 2-ME2

Although Bcl-2 overexpression has been associated with enhanced NF-κB activity [57–61], NF-κB’s contribution to 2-ME2-induced apoptosis has remained elusive [18,27]. To investigate the effects of 2-ME2 on NF-κB signaling, total cell lysates, cytoplasmic and nuclear extracts and proteins from isolated nuclei were analyzed by immunoblotting for expression of IκBα and canonical p50 and p65 NF-κB subunits (Fig. 6). No changes in the expression of the total levels of either p50 or p65 were detected in
Jurkat, Jurkat Puro or Jurkat Bcl-2 cells in the absence or presence of 2-ME2 (Fig. 6A). However, after exposure to 2-ME2, phospho-IκBα levels increased in conjunction with IκBα being reduced in all Jurkat cell types. Total and phospho-IκBα levels were much lower in untreated and 2-ME2-treated Jurkat Bcl-2 than in Jurkat Puro cells most likely due to IκBα’s rapid phosphorylation and degradation in the context of Bcl-2 overexpression (Fig. 6A). Thus NF-κB was activated by 2-ME2 treatment and NF-κB was also more active in Jurkat Bcl-2 cells than their control counterparts. While both Jurkat Puro and Jurkat Bcl-2 cells contained much higher levels of p50 in nuclear than in cytoplasmic extracts, the opposite was observed for p65 (Fig. 6B) and the nuclear levels of p50 were higher in Jurkat Bcl-2 than in Jurkat Puro cells even in the presence of 2-ME2 (Fig. 6B and S2). To verify these results, total proteins from isolated nuclei were probed for the expression of NF-κB p50 and p65 (Fig. 6C). Indeed, Jurkat Bcl-2 cells expressed higher nuclear levels of NF-κB p50 but the basal and 2-ME2-induced levels of nuclear p65 were similar to those detected in Jurkat Puro cells (Fig. 6C). The higher nuclear-associated expression of Bcl-2 in Jurkat Bcl-2 cells could have facilitated p50 nuclear transport. However, no specific binding of Bcl-2 to either p50 or p65 subunits was detected (data not shown), suggesting that higher levels of nuclear p50 in Jurkat Bcl-2 cells were most likely indirectly due to their maintenance of nuclear membrane integrity. Confocal laser scanning microscopy showed that Jurkat Bcl-2 cells specifically contained higher levels of p50–p65 heterodimers in their nuclei and also that 2-ME2-induced the accumulation of p50 and p65 in the nuclei of the few undamaged 2-ME2-treated Jurkat Puro cells and in the intact nuclei of most Jurkat Bcl-2 cells (supplementary information and Fig. S2).

To investigate whether the higher levels of nuclear NF-κB p50–p65 heterodimers in Jurkat Bcl-2 cells correlated with increased NF-κB transcriptional activity, total cells lysates from untreated and 2-ME2-treated Jurkat Puro and Jurkat Bcl-2 cells were probed for the expression of Pim-2, a serine/threonine kinase and a direct NF-κB target gene with putative anti-apoptotic properties [43,62] (Fig. 6D). Whereas, Pim-2 expression was down-regulated in Jurkat Puro in response to 2-ME2, its expression was sustained in Jurkat Bcl-2 cells (Fig. 6D), in agreement with the activated state of NF-κB in these cells as also shown by confocal microscopy (Fig. S2).

3.6. Suppression of canonical NF-κB activity sensitized Jurkat cells to apoptosis

In order to further confirm that NF-κB activity contributed to increased resistance of Jurkat Bcl-2 cells to 2-ME2-induced apoptosis, an IκBα super repressor (IκBαSR) [43] was used to suppress NF-κB signaling pathway in both Jurkat and Jurkat Bcl-2 cells. As expected, cells retrovirally transduced with IκBαSR expressed higher levels of IκBα compared to their control counterparts (Fig. 7A). As the human p27Kip1 gene promoter contains an NF-κB-responsive element [63], we investigated whether there was a link between NF-κB and p27Kip1 expression, which both contribute to increased resistance of cells to apoptosis. The levels of p27Kip1 and Pim-2 were reduced, albeit modestly, in proliferating Jurkat Bcl-2/IκBαSR compared to Jurkat Bcl-2 cells but such reductions were not as obvious in confluent cultures (Fig. 7B). Furthermore, DNA analysis showed that IκBαSR expressing Jurkat Bcl-2 cells were more sensitive to 2-ME2-induced apoptosis (Fig. 7C).

3.7. p27Kip1 knock-down sensitized Jurkat cells to 2-ME2-induced apoptosis

To determine if higher p27Kip1 levels were a critical factor contributing to the resistance of Jurkat Bcl-2 cells to 2-ME2-induced apoptosis [49,56], we knocked-down p27Kip1 expression by RNA interference [42]. Immunoblotting showed that the stable introduction of a p27Kip1 shRNA into Jurkat and Jurkat Bcl-2 cells markedly reduced p27Kip1 expression compared to their control counterparts (Fig. 8A). Analysis of low molecular weight DNA on agarose gels revealed that p27Kip1 KD Jurkat cells were sensitized to spontaneous apoptosis (Fig. 8B) and importantly p27Kip1 KD Jurkat Bcl-2 cells were also more prone to 2-ME2-induced apoptosis (Fig. 8C). Thus, on the basis of the above results and our other findings with IκBαSR expressing cells, p27Kip1 is functionally linked to the resistance of Jurkat Bcl-2 cells to 2-ME2-induced apoptosis.
cell types were analyzed by immunoblotting for the expression of p27Kip1 or bearing shRNA to p27Kip1 or a control vector to generate Jurkat Vec, Jurkat p27KD, apoptosis. Jurkat and Jurkat Bcl-2 cells were infected with recombinant retrovirus phosphorylation and inactivation of Bcl-2[7,15,27–29]. However, mechanisms studied in different cellular systems including apoptosis of tumor cells but not of normal cells, through several

4. Discussion

Fig. 8. Reduction of p27Kip1 levels sensitized Jurkat and Jurkat Bcl-2 cells to apoptosis. Jurkat and Jurkat Bcl-2 cells were infected with recombinant retrovirus bearing shRNA to p27Kip1 or a control vector to generate Jurkat Vec, Jurkat p27KD, Jurkat Bcl-2/Vect and Jurkat Bcl-2/p27KD cells. (A) Total lysates from all the different cell types were analyzed by immunoblotting for the expression of p27Kip1 or β-actin. (B) and (C) Low molecular weight DNA was isolated from untreated, ethanol- or 2-ME2-treated Jurkat/Vect and Jurkat p27KD cells (B) or Jurkat Bcl-2/Vect and Jurkat Bcl-2/p27KD cells (C), as indicated and analyzed by agarose gel electrophoresis. Vec, vector pSRT-Puro. All experiments were repeated twice with comparable results.

4.1. 2-ME2-induced apoptosis in leukemia cells involved effects on multiple parameters: JNK activation and Bcl-2: Bax ratio

2-ME2-induced apoptosis of leukemic [26,29] and prostate cancer [15,27] cells has been associated with JNK-dependent phosphorylation, Akt inactivation [26] along with Bcl-2 phosphorylation; but the precise roles of these events in the ensuing apoptotic responses have remained elusive [34]. The role of Bcl-2 phosphorylation in the regulation of apoptosis is unclear, since some studies showed inactivation of its anti-apoptotic function [36–39,65], while others showed potentiation of its anti-apoptotic function [35,55,66]. The data presented here were in support of the latter, in that 2-ME2 induced Bcl-2 phosphorylation was well correlated with the accumulation of the phosphorylated, activated forms of JNK/SAPK in Jurkat cells [15,26-29]. Members of the Bcl-2 family are major regulators of mitochondrial apoptotic events. Anti- (Bcl-2 and Bcl-XL) and pro- (Bax and Bak) apoptotic Bcl-2 proteins regulate apoptosis in part by controlling Cytochrome c release from mitochondria. The ratio between pro- and anti-apoptotic proteins determines in part the susceptibility of cells to a death signal [31–33]. Previous studies showed that Bak played a key role in the mitochondrial apoptotic response of Jurkat cells induced by UV or anticancer drugs [47,48]. 2-ME2 induced the expression levels of Bak, albeit modestly, in Jurkat and Jurkat Puro cells but not in Bcl-2-expressing cells. In addition, no changes in the protein levels of Bax and PUMA were detected in any cell type following treatment with 2-ME2 (data not shown). Thus, whether 2-ME2 either interfered with the dimerization of Bcl-2 to Bak [37,38] or resulted in the inactivation of Bcl-2, through the induction of Bcl-2 phosphorylation (and down-regulation), allowing Bak to initiate apoptosis [31–33], it changed the ratio of anti- to pro-apoptotic (Bcl-2:Bak) members of the Bcl-2 family towards the latter thus driving the cell towards cell death. The latter most likely occurred via the mitochondrial pathway as shown by the activation of caspasases-9, caspase-3 and PARP-1 cleavage; (3) enforced expression of Bcl-2 blocked 2-ME2-induced apoptosis of Jurkat cells by inducing G1/S cell cycle phase arrest that correlated with changes in the expression of proteins involved in cell cycle progression and apoptosis; (4) Bcl-2 protein was found to be nuclear-associated leading to higher NF-κB activity, as documented by the sustained expression of Pim-2, and to higher nuclear levels of p27Kip1 in Jurkat Bcl-2 cells following treatment with 2-ME2, which occurred at least in part due to their maintenance of nuclear integrity; (5) suppression of NF-κB signaling sensitized Jurkat Bcl-2 cells to 2-ME2-induced apoptosis, through down-regulation of p27Kip1; and (6) knocking-down the expression levels of p27Kip1 resulted in spontaneous Jurkat cell apoptosis and to the loss of Bcl-2 anti-apopotic activity in Jurkat Bcl-2 cells following treatment with 2-ME2. Collectively, our data have dissected the molecular basis by which 2-ME2 induced apoptosis of Jurkat leukemia cells and also by which Bcl-2 suppresses these 2-ME2-induced effects on cell physiology. 2-ME2 induced apoptosis of Jurkat cells in a dose- and time-dependent manner as demonstrated by DNA fragmentation and flow cytometric analysis. The induction of apoptosis by 2-ME2 was p53-independent as Jurkat cells bear a mutant p53 allele [64] and correlated with down-regulation and phosphorylation of Bcl-2. Treatment of several cell lines with chemotherapeutic agents that perturb tubulin microtubules resulted in phosphorylation of Bcl-2 during apoptosis [34,38,39,65]. However, Bcl-2 phosphorylation was not detected in cells treated with pro-apoptotic drugs that do not affect microtubule dynamics suggesting that microtubule damage may trigger Bcl-2 phosphorylation and that one of the functions of Bcl-2 may be to monitor microtubule integrity [38,39].
involved JNK activation mediating Bcl-2 phosphorylation, hence inactivation, leading to an altered Bcl-2:Bak ratio that simultaneously yield to mitochondrial-dependent programmed cell death.

4.2. The molecular basis for Bcl-2 mediated protection of leukemia cells to 2-ME2-induced apoptosis involved a G1/S cell cycle arrest

Interestingly, Bcl-2-mediated apoptotic block to 2-ME2 was linked to G1/S cell cycle arrest following 2-ME2-treatment of the cells, through changes in the expression of cell cycle regulators. Whereas in Jurkat and Jurkat Puro cells treatment with 2-ME2 down-regulated the expression of the G1 cyclin, cyclin D3, in Jurkat Bcl-2 cells the levels of cyclin D3 were higher than their control counterparts and were sustained following 2-ME2-treatment. Down-regulation of cyclin D3 was shown in Jurkat and Jurkat Puro cells by 2-ME2 was due to apoptosis leading to fewer cells progressing through the cell cycle as documented by flow cytometry. In contrast, higher levels of cyclin D3 detected in Bcl-2-expressing cells were most likely due to accumulation of live cells in the G1 phase following treatment with 2-ME2, and to higher NF-kB activity in these cells. The Cyclin D3 gene is rearranged and the protein is overexpressed in several human lymphoid malignancies [67]. Cyclin D3-/- animals fail to undergo normal expansion of immature T lymphocytes and show greatly reduced susceptibility to T cell malignancies triggered by specific oncogenic pathways. Further, knock-down of cyclin D3 inhibited proliferation of acute lymphoblastic leukemias deriving from immature T lymphocytes, suggesting a requirement of cyclin D3 in the development of T cell leukemias [67]. The finding that 2-ME2 down-regulated cyclin D3 in human Jurkat T leukemic cells and its sustained expression in Bcl-2-expressing Jurkat cells would be in keeping with these studies. A reduction in the levels of cyclin E by 2-ME2 in all the different cell types suggested that 2-ME2 affected G1 to S cell cycle progression [68].

Cell cycle progression relies on the activation of cyclins and CDKs which successively act together in G1 to initiate S phase and in G2 to initiate mitosis. To prevent abnormal proliferation, cyclin-CDK complexes are precisely regulated by two families of cell cycle inhibitors that block their catalytic activity [69]. The first class of inhibitors includes the INK4a proteins that bind to Cdk4/6 kinases and not to cyclins and are therefore specific for early G1 phase. The second family of inhibitors is composed of Cip/Kip proteins, such as p21Cip1/Waf1 and p27Kip1, that inhibit all cyclin-CDK complexes and are not specific for a particular phase. Unlike INK4a, Cip/Kip proteins do not dissociate cyclin-CDK complexes [69]. However, other studies suggested that p21Cip1/Waf1 and p27Kip1 might have new activities, that are unrelated to their function as CDK inhibitors, such as the regulation of apoptosis and in transcriptional activation [70].

The induction of p16INK4A by 2-ME2 in Jurkat and Jurkat Puro cells probably contributed to two outcomes: inhibition of cell proliferation and also cell apoptosis induced by 2-ME2. However, because p16INK4A was not induced by 2-ME2 in Bcl-2-expressing cells, up-regulation of p16INK4A would seem to be more likely involved in 2-ME2-induced apoptosis rather than in growth inhibition, and several other studies have pointed towards a role of p16INK4A in drug-induced apoptosis of tumor cells [71,72].

2-ME2 treatment resulted in the down-regulation and phosphorylation of p21Cip1/Waf1, p27Kip1/Waf1 functions both as a positive and negative regulator of the cell cycle by regulating both CDK activity and DNA synthesis, but it also appears to play a role in enhancing cell survival [69,70,73,74]. Further, it appears that the switch between cell cycle promotion and inhibition by p21Cip1/Waf1 may occur by virtue of the subcellular localization of this protein through phosphorylation [73,74]. Treatment of Jurkat cells with 2-ME2 resulted in the down-regulation and phosphorylation of p21Cip1/Waf1 in all the different Jurkat cell types, which did not correlate with apoptosis. To clarify the role of p21Cip1/Waf1 in 2-ME2-induced apoptosis, p21Cip1/Waf1 was ectopically over-expressed in Jurkat cells and it neither induced growth arrest nor protected the cells from 2-ME2-induced apoptosis (data not shown). Hence, phosphorylation of p21Cip1/Waf1 following treatment with 2-ME2 probably affected its function as an assembly factor of cyclin D-CDK4/6 complexes, which function as sensors of growth factors at G1/S phase [69,70,73,74].

In contrast to p16INK4A and p21Cip1/Waf1, 2-ME2 did not affect the expression of p27Kip1 in all the different Jurkat cell types. However, Jurkat Bcl-2 cells expressed elevated levels of p27Kip1 compared to their control counterparts, accounting for their reduced growth rates. This negative effect of Bcl-2 on cell proliferation was in agreement with previous studies [49,75–79], through elevation of p27Kip1 [49,53–55] and to its role in T cell survival [80,81].

In summary, our results showed that in control cells 2-ME2 down-regulated the expression of cyclin D3, cyclin E, and E2F1, down-regulated and phosphorylated p21Cip1/Waf1, and also induced the expression of p16INK4A, without affecting the levels of p53 and p27Kip1. In contrast, in Jurkat Bcl-2 cells the levels of cyclin D3 and p27Kip1 were elevated and sustained, and no induction of p16INK4A was detected following treatment with 2-ME2. These data taken together with the growth curves and flow cytometry analyses suggested that Jurkat Bcl-2 cells were arrested in G1/S phase of the cell cycle, most likely at the restriction point.

4.3. Bcl-2-induced cell cycle arrest is caused by the NF-κB-dependent enhancement of p27Kip1 expression

To get some insight into the mechanism by which Bcl-2 arrested growth following treatment with 2-ME2, we analyzed the expression and subcellular localisation of Bcl-2 and p27Kip1. We demonstrated that Bcl-2 and p27Kip1 were predominantly nuclear-associated and that Bcl-2 expression most likely enhanced nuclear levels and perhaps the stability of p27Kip1. Given the role of p27Kip1 in the regulation of cell cycle progression and apoptosis [56,81], the elevated levels of p27Kip1 in Bcl-2-expressing cells could account for both the reduced growth rate or G1/S arrest [49] following treatment with 2-ME2 but also for the increased resistance [56] to 2-ME2-induced apoptosis.

p27Kip1 expression is regulated at the posttranscriptional level, both at the level of protein translation and stability. The cyclin E/CDK2 complexes are the major target of p27Kip1 inhibitory activity, but on the other hand p27Kip1 can act as a substrate for cyclin E/CDK2 complexes. Once activated, cyclin E/CDK2 complexes phosphorylate p27Kip1 at Thr187, thereby triggering its Skp2-dependent ubiquitination and degradation by the proteasome complex [56]. Initially, p27Kip1 binds with low affinity acting as a substrate, and then slowly the binding shifts to high affinity and p27Kip1 becomes an inhibitor. At equilibrium, p27Kip1 inhibits cyclin E/CDK2 activity and this provides a negative regulatory feedback loop that makes G1/S transition irreversible [56]. In addition, p27Kip1 is phosphorylated at Ser10 accounting for 70% of the total phosphorylation of the protein. In contrast to Thr187, Ser10 phosphorylation increases the stability of the protein [56]. Whereas, the S-phase degradation of p27Kip1 is Thr187 and Skp2-dependent, the degradation of p27Kip1 at the G1 restriction point is independent of these but dependent on mitogen stimulation.

Previous studies showed that stable overexpression of Bcl-2 enhanced [57,58], preserved [59] or had no effect [60,61] on NF-kB activity. Further, nuclear compartment-associated Bcl-2 was
previously reported in lymphoid cells [50], during aging and oxidative stress [51] and nuclear localization of transfected Bcl-2 interfered with the nuclear import of NF-κB subunits in non-lymphoid cells, thus inhibiting their activity [52], but nuclear Bcl-2 was not detected in untransfected cells [51,52]. Biochemical and immunostaining techniques showed that Bcl-2-expressing Jurkat cells contained higher levels and activity of NF-κB, as documented by the maintenance of Pim-2 and NF-κB levels would appear to be indirect. One plausible explanation for this intriguing (albeit indirect) connection between Bcl-2 and NF-κB could perhaps be that higher levels of nuclear-associated Bcl-2 protein help to maintain nuclear stability, which then somehow contribute to higher nuclear levels and activity of NF-κB and also to higher nuclear levels and stability of p27kip1. However, the indirect effect of nuclear Bcl-2 on NF-κB and also p27kip1 appears to be at least somewhat specific, because other transcription and cell cycle regulators are not similarly affected [52] (see our observations on E2F1 along with several other effectors of cell cycle progression in Fig. 4).

To investigate a link between the roles of NF-κB and p27kip1 in 2-ME2-induced apoptosis but also their contribution to resistance to 2-ME2 exhibited by Jurkat Bcl-2 cells, we interfused with NF-κB signaling pathway and p27kip1 expression. Suppression of NF-κB signaling using a super repressor, lKoSR, sensitized Jurkat Bcl-2 cells to 2-ME2-induced apoptosis, through down-regulation of p27kip1. Knocking-down p27kip1 expression led to spontaneous Jurkat cell apoptosis and sensitized Jurkat Bcl-2 to 2-ME2-induced apoptosis.

Collectively these data show that Bcl-2 protected Jurkat cells from 2-ME2-induced apoptosis by multiple mechanisms including: inhibition of the mitochondrial apoptotic pathway, maintenance of nuclear integrity via its nuclear-association, maintaining active nuclear NF-κB resulting in higher levels of Pim-2 (a direct NF-κB target with potent anti-apoptotic properties) and finally to enhanced levels and stability of p27kip1, which was recently reported to be a direct NF-κB-target gene [82]. On the basis of these results we have achieved a much better understanding of the penetrance and mechanistic complexity of Bcl-2 dependent anti-apoptotic pathways in cancer cells and why Bcl-2 inactivation is so critical for the efficacy of apoptosis and anti-proliferative inducing drugs like 2-ME2.

**Conflict of interest**

The authors have no conflicting financial interests.

**Acknowledgements**

We are grateful to Dr. D. Tang, University of Montreal, Canada for providing pBabe-Puro/hBcl-2, Dr. J. Chen, H. Lee Moffitt Cancer Center & Research Institute, The University of South Florida, USA, for p5SR-Puro and p5SR-Puro#p27kip1, and Drs C.J. Sherr and M. Roussel, Department of Genetics, St. Jude Children’s Research Hospital, Memphis, Tennessee, USA, for providing p21S(353)Wat and p27kip1 retroviral vectors. We also thank Drs S. Georgatos, C. Murphy and F. Pappas, University of Ioannina Medical School, Greece, for providing rabbit polyclonal anti-lamin B and reagents. This work was supported by a bilateral agreement grant from the General Secretariat of Research and Technology, Greece (E. Kolettas, 61/1722) and the Cyprus Research Promotion Foundation (A. Constantinou; ENTKS/0505/S2).

**Appendix A. Supplementary data**

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.bcp.2009.03.017.

**References**

Kaufmann JA, Perez M, Zhang WR, Bickford PC, Holmes DB, Taglialatela G. Free
Zinkel S, Gross A, Yang E. BCL2 family in DNA damage and cell cycle control.
Wang G-Q, Wieckowski E, Goldstein LA, Gastman BR, Rabinovitz A, Gambotto
Reddy KB, Karode MC, Harmony JAK, Howe PH. Transforming growth factor
Pathan N, Aime-Sempe C, Kitada S, Basu A, Haldar S, Reed JC. Microtubule-
Haldar S, Chintapalli J, Croce CM. Taxol induces bcl-2 phosphorylation and
Srivastava RK, Mis QS, Hardwick JM, Longo DL. Deletion of the loop region of
Yamamoto K, Ichijo H, Korsmeyer SJ. Bcl-2 is phosphorylated and inactivated
Borriello A, Cucciolla V, Oliva A, Zappia V. p27Kip1 metabolism. Cell